Recent Jobs

  • Regulatory Affairs Associate

    Regulatory Professionals
    Buckinghamshire, Berkshire, >UK
  • Director of Regulatory CMC

    Regulatory Professionals
    UK, Cambridgeshire
  • Regulatory Packaging and Artwork Project Manager

    Regulatory Professionals
    UK, Surrey
  • Senior / Principle Regulatory Consultant

    Regulatory Professionals
    UK, Hertfordshire
Load more listings

Featured Job

Regulatory Affairs Associate

Reference Number: J32422 Regulatory Affairs Associate Location: Berkshire Salary: Up to £40,000 + company benefits Job Reference: J32422 Our client:

Make your job search easier

Create a candidate account to save jobs for later and have the latest roles and career advice emailed to you.

Register for Job Alerts

Create an Account

Complete your online profile and make it easier to apply for roles on the move.

Register your Details

Want to see how you compare to the rest of the industry?

Enter your details to receive a complimentary copy of our salary guide delivered to your door.

Life Science Salary Guide

Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.

Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.

Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.

The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.

Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.

To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:

•    Regulatory Medical Devices
•    Regulatory Clinical
•    Regulatory CMC
•    Regulatory Submissions and Publishing
•    Regulatory Writing
•    Lifecycle Management

Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.

+44 (0)118 9522 797

Contact us today to find out how we can progress your career to the next level

Latest News

NICE backs EUSA’s RCC treatment Fotivda

EUSA Pharma has gained backing from NICE for its first-line treatment for advanced renal cell carcimona (RCC), Fotivda. The recommendation from the UK’s regulatory body was decided on the result of the phase III trial TiVO-1, which evaluated the efficacy and tolerability of Fotivda compared to Bayer’s Nexavar.

Continue Reading

NICE recommends Roche’s breast cancer treatment, Perjeta

NICE issues final green light and thus securing routine NHS funding for Roche’s Perjeta in patients with a certain type of breast cancer. The guidelines follow a confidential commercial agreement for Perjeta between NHS England and the Roche late last year, allowing for its move from the Cancer Drugs Fund to the NHS’ routine commissioning

Continue Reading